A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 07 May 2014
At a glance
- Drugs Motolimod (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors VentiRx Pharmaceuticals
- 07 Jun 2011 Results were presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
- 21 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 04 Oct 2010 Status changed from recruiting to completed.